GEMCITABINE ACTAVIS 200 MG/VIAL

국가: 이스라엘

언어: 영어

출처: Ministry of Health

유효 성분:

GEMCITABINE 200 MG/VIAL

제공처:

DEVRIES & CO. LTD

ATC 코드:

L01BC05

약제 형태:

POWDER FOR SOLUTION FOR INFUSION

관리 경로:

I.V

Manufactured by:

ACTAVIS GROUP PTC ehf, ICELAND

치료 그룹:

GEMCITABINE

치료 징후:

Gemcitabine is indicated for the treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas.Gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Gemcitabine monotherapy can be considered in elderly patients or those with performance status 2. Gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first-line therapy. Gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherap

승인 날짜:

2013-06-01